<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179397</url>
  </required_header>
  <id_info>
    <org_study_id>SC9-0015</org_study_id>
    <nct_id>NCT03179397</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Model SC9 IOL Compared to the Model LI61SE IOL (Bausch &amp; Lomb)</brief_title>
  <official_title>A Clinical Trial to Evaluate the Safety and Effectiveness of Model SC9 Silicone IOL for the Visual Correction of Aphakia Secondary to the Removal of a Cataractous Lens in Adult Patients With or Without Presbyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CORD, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CORD, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the Model SC9 Intraocular Lens for the improvement of near and intermediate
      vision when compared to a legally marketed monofocal IOL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized to one of two groups. Group A, (Test Lens, Model SC9) or Group B,
      (Control Lens, Model LI61SE, Bausch and Lomb).

      Both groups will be randomized to receive either unilateral or bilateral implantation. No
      bilateral implantation is allowed in Phase 1. (50 subjects).

      Subjects will be followed for 36 Months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Enrolled subjects will not be told which IOL they have received until the end of the study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Visual Acuity Measurements using the LogMar Scale</measure>
    <time_frame>12 Months</time_frame>
    <description>Subjects must read 20/40 or better, distance corrected near visual acuity and 20/40 or better distance corrected intermediate visual acuity. This is achieved with the subject wearing their best corrected spectacle correction in place and reading a series of letters at 40cm/16&quot; and 80cm/32&quot;. Total letters read for each line will determine their visual acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Defocus testing in 0.5D increments from -0.5 to -5.00D</measure>
    <time_frame>12 Months</time_frame>
    <description>A sub-set of 50 subjects will undergo defocus testing with their best distance correction in place. Minus Lenses in 0.5D increments will be placed over their best spectacle correction. Total letters read for each diopter will be recorded. Percentage of eyes with improvement of monocular depth of focus by at least 0.5D mean difference between the Model SC9 and control lens.(significance level of 0.025). To demonstrate superiority of at least 0.5D compared to the control lens &gt;75% of eyes implanted with the Model SC9 should demonstrate superiority by at least 0.5D mean difference compared to the control lens.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Model SC9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational IOL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Model LI61SE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FDA Approved IOL</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Model SC9</intervention_name>
    <description>Experimental</description>
    <arm_group_label>Model SC9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Model LI61SE</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Model LI61SE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Twenty-two years or older at the time of surgery and diagnosed with bilateral
             cataracts

          -  Able to comprehend and sign a statement of informed consent

          -  Willing and able to complete all required postoperative visits

          -  Calculated Lens Power within the available range for the study IOL's

          -  Planned cataract removal by phacoemulsification

          -  Potential postoperative visual acuity of BCDVA 0.2 LogMAR (20/32) or better in both
             eyes

          -  Subjects with less than 1.0D of corneal astigmatism

          -  Clear intraocular media other than cataract in the study eye

          -  Preoperative BCDVA worse than 0.2 LogMar (20/32) with or without glare

          -  Pupil size greater or equal to 6.0mm after dilation

        Exclusion Criteria:

          -  Any corneal abnormality, other than regular corneal astigmatism

          -  Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or
             other retinal disorders) that are predicted to cause future acuity losses to a level
             worse than 0.2 LogMAR (20/32)

          -  Previous refractive surgery

          -  Amblyopia

          -  Clinical severe corneal dystrophy (e.g., epithelial, stromal, or endothelial
             dystrophy)

          -  Diabetic retinopathy

          -  Extremely shallow anterior chamber, not due to swollen cataract

          -  Microphthalmos

          -  Previous retinal detachment

          -  Previous corneal surgery

          -  Recurrent severe anterior or posterior segment inflammation of unknown etiology

          -  Rubella or traumatic cataract

          -  Iris Neovascularization

          -  Glaucoma (uncontrolled or controlled with medication)

          -  Aniridia

          -  Optic nerve atrophy

          -  Damaged incomplete zonules

          -  Systemic disease that could increase the operative risk or confound the outcome

          -  Medications that, in the opinion of the investigator may confound the outcome or
             increase the risk to the subject (tamsulosin hydrochloride (Flomax) or other
             medications with similar side-effects (floppy iris syndrome)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Stuart Cumming, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>CORD, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan B Aker</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aker-Kasten Eye Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynne Archer</last_name>
    <phone>714-651-6333</phone>
    <email>larcher@cordsc9.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Kramsky</last_name>
    <email>pkramsky@cordsc9.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Harvard Eye Associates</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Edwards</last_name>
      <phone>949-842-9954</phone>
      <email>nedwards@harvardeye.com</email>
    </contact>
    <investigator>
      <last_name>John Hovanesian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Vision Laser Eye Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Edwards</last_name>
      <phone>949-842-9954</phone>
      <email>nedwardsresearch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dan B Tran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aker-Kasten Eye Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Di Rico - Truax, COMT</last_name>
      <phone>561-338-7722</phone>
      <phone_ext>331</phone_ext>
      <email>ltruax@akerkasten.com</email>
    </contact>
    <investigator>
      <last_name>Alan B Aker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jill F Rodila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Eye Institute of West Florida</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Bondurant, BS</last_name>
      <phone>727-450-4668</phone>
      <email>Renee.Bondurant@eyespecialist.com</email>
    </contact>
    <investigator>
      <last_name>Robert Weinstock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Vision Institute</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nic Jacobs</last_name>
      <phone>952-835-4768</phone>
      <email>nic.jacobs@chuvision.com</email>
    </contact>
    <investigator>
      <last_name>Y. Ralph Chu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carter Eye Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delbert Hensley</last_name>
      <phone>214-750-1962</phone>
      <email>dhensley@cartereye.com</email>
    </contact>
    <investigator>
      <last_name>Harvey L Carter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

